USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AVANTGEN, INC.
Address:
AVANTGEN, INC.
10151 Pacific Mesa Blvd.
SAN DIEGO, CA 92129-4571
Phone:
N/A
URL:
N/A
EIN:
120215784
DUNS:
186489899
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,077,523.00 8
SBIR Phase II $2,502,768.00 3

Award List:

A novel therapeutic antibody for treatment of ischemic stroke.

Award Year / Program / Phase:
2008 / SBIR / Phase I
Award Amount:
$220,061.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the United States. Despite its prevalence, current treatment options are limited and surviving stroke is still associated with serious morbidity issues. The most recent ther apy for ischemic stroke, Alteplase, was… More

Novel human anti-uPAR antibodies for the treatment of pancreatic cancer

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$158,025.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Cancers that are typically diagnosed as late-stage, metastatic disease, such as pancreatic cancer, have remained refractory to standard radiation, surgical and chemotherapy. With all the advance of newer more targeted a gents, pancreatic cancer 5-year mortality… More

RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$149,951.00
Agency:
HHS
Principal Investigator:
Xiaomin Fan – (858) 538-9866
Abstract:
Not Available

DEVELOPMENT OF ALTERNATIVE AFFINITY CAPTURE REAGENTS FOR CANCE

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$150,000.00
Agency:
HHS
Principal Investigator:
Xiaomin Fan – (858) 538-9866
Abstract:
With the advances in proteomics, thousands of cancer biomarker candidates have been discovered. To fully validate these candidate cancer markers and eventually translate them into clinical use, it is essential to  establish a comprehensive, highly characterized and standardized collection of… More

Endothelial Lipase: a novel therapeutic target for HDL and atherosclerosis

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$277,115.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): There is mounting evidence indicating that endothelial lipase (EL) plays a key role in the regulation of circulating cholesterol levels by modulating high-density lipoprotein-cholesterol (HDL-C) levels and hence reverse cholesterol transport. Therefore, EL… More

RENEWABLE CAPTURES FOR ADDICTION-RELEVANT PROTEINS

Award Year / Program / Phase:
2010 / SBIR / Phase II
Award Amount:
$764,548.00
Agency:
HHS
Principal Investigator:
Xiaomin Fan – (858) 538-9866
Abstract:
The overall objective of the proposed scope of work for this Phase II contract is to leverage AvantGen's proprietary yeast display technology and synthetic human antibody library to isolate renewable capture agents against neuroscience proteins of interest in a more rapid, cost effective-manner. … More

A novel approach for developing GPCR subtype specific antibodies

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$697,427.00
Agency:
HHS
Principal Investigator:
Xiaomin Fan – 858-538-9866
Abstract:
DESCRIPTION (provided by applicant): Despite the prevalence of serious mental illness, our current understanding of the pathophysiology of mental disorders is limited. In part, this is due to the complexity of the CNS and difficulty of recapitulating suchillnesses in animal models. While G-protein… More

IGF::OT::IGF OTHER FUNCTIONS SBIR PHASE II, TOPIC 288, RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$747,441.00
Agency:
HHS
Principal Investigator:
Xiaomin Fan – 858-768-8107
Abstract:
The objective of this proposed project is to develop recombinant antibodies against 75 cancer-related proteins. In the Phase I study, we have demonstrated that multiple antibody clones could be isolated from a large yeast displayed human antibody library.The isolated antibodies exhibit high affinity… More

OTHER FUNCTIONS - RECOMBINANT ANTIBODIES AS AFFINITY CAPTURES

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$990,779.00
Agency:
HHS
Principal Investigator:
Xiaomin Fan – 858-768-8107
Abstract:
One of the biggest roadblocks to the translation of basic proteomic discoveries to potential clinical applications is the lack of robust and sensitive reagents that can capture a given protein reproducibly from different types of matrixes. While antibodieshave been the major players of protein… More

Development of an Intraoral Optical Probe for the Microscopic Evaluation of Denta

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$224,957.00
Agency:
HHS
Principal Investigator:
Xiaomin Fan – 858-768-8107
Abstract:
DESCRIPTION (provided by applicant): The development of addiction involves the dopaminergic reward pathway and downstream negative changes that lead to craving and repeat self-administration. While it is clear this process involves changes in neuronal plasticity t the synapse junction, the exact… More

TOPIC 319 PHASE I; RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AS AFFINITY CAPTURES

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$199,987.00
Agency:
HHS
Principal Investigator:
Xiaomin Fan – 858-768-8107
Abstract:
Recombinant rabbit monoclonal antibodies as affinity captures for peptides PUBLIC HEALTH RELEVANCE